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diagnosed with symptomatic MM.
Study design: Descriptive, cross-sectional.
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35Patient, physician and contextual factors are inﬂuential in the treatment decision makingConclusions: Treatment decision making in older adults newly diagnosed with symptomatic
myeloma is inﬂuenced by personal, social and contextual factors. Patients must be given the
opportunity to choose the best possible treatment within the limits of the patient’s personal, social
and medical contexts.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Multiple myeloma (MM) is a cancer of the plasma cells
affecting primarily the elderly, with the highest incidence
occurring at the sixth through the eighth decade of life [1].
In 2012, there were approximately 21,700 new cases
diagnosed in the U.S., making MM the second most common
hematologic malignancy after non-Hodgkin’s lymphoma [2].
The overall annual incidence rate of MM in the U.S. from
1973 to 2005, age-adjusted to the 2009 population, was
11.0 and 4.3 per 100,000 person-years for blacks and
whites, respectively [3]. Worldwide, MM has incidence rate
from 0.4 to 5 persons per every 100,000 on a given year,
with rates being higher in Western than in Asian countries
[4,5]. MM is not curable; however, there are many effective
treatments available that can extend patient overall survi-
val with relatively good quality of life (QOL) [6].
The ﬁndings of randomized controlled trials (RCTs) com-
paring conventional versus high dose chemotherapy (HDT)
followed by autologous hematopoietic stem cell transplan-
tation (HSCT) show equivocal results in terms of overall
survival, though they do show that the HDT offers longer
progression-free survival [7,8]. Autologous HSCT is still
widely accepted as a treatment option for MM patients
o65 years of age, yet it is now being challenged through
historical control studies and RCTs comparing outcomes
from HDT versus non-intensive therapy using novel therapies
such as thalidomide, bortezomib, lenalidomide and carﬁl-
zomib [9,10]. Currently, there is an ongoing RCTs comparing
HDT followed by autologous HSCTwith novel therapies [11].
Evidence-based treatment guidelines developed by the
National Comprehensive Cancer Network, an organization of
21 leading comprehensive cancer centers in the US, do not
identify one treatment as unequivocally superior to all
alternatives for a given set of conditions [12]. MM treat-
ments come in various forms, routes and intensities,
including oral chemotherapies, IV chemotherapies and
HDT or reduced intensity therapy followed by autologous
HSCT. Other factors such as direct cost to the patient (co-
pays and deductibles) and insurance coverage status may
also inﬂuence treatment decisions. It is unclear how these
variables ultimately inﬂuence actual treatment choices in
older adults newly diagnosed with symptomatic MM.
Advances in MM genomics are beginning to shed some
understanding on the role of genetic aberrations in the
success rates of various MM therapies, adding still more
complexity and uncertainty during treatment decision mak-
ing (TDM) [18,19]. There is no doubt that the advent of
novel therapies showing similar (or sometimes better)
response rates when compared historically to the outcomes
from traditional therapies (e.g., high dose dexamethasone)
creates further clinical uncertainties in TDM [20–23].Given the lack of one recognized “best” medical therapy,
patients hear about the many available options and are in a
position to select, along with the specialist, one or more
treatments among others. With other cancer diagnoses in
which adults have multiple treatment choices, there is
evidence that personal factors and preferences are quite
inﬂuential in determining how patients arrive at a ﬁnal
treatment decision [13,14]. Similarly, physician preferences
and values have also been found to be inﬂuential in actual
treatment decisions [15–17].
Research studies that examine not only the physician’s
perspectives, but also those of the patient, can inform both
clinicians and policy makers on how to improve outcomes
related to TDM. By exploring and understanding patient
preferences and values, clinicians will be better prepared to
engage in shared decision making with patients diagnosed
with symptomatic MM. Information on TDM is particularly
relevant for the elderly with MM, who may have a different
set of values and preferences than younger patients.
Conversely, by understanding physician perspectives, policy
makers and medical practice administrators will have a
broader view of the process and may be able to support
innovative strategies that will enhance physician–patient
TDM encounters.1.1. Treatment considerations in older adults
There are speciﬁc treatment considerations in older adults
with cancer. Age is likely to be an inﬂuential factor in TDM
by both patients and clinicians. Berry and colleagues [24]
found evidence of this in a study of 260 men with localized
prostate cancer. A majority (70%) of the study participants
reported that their age had inﬂuenced their treatment
decision, with older men being more likely to eliminate a
particular treatment option exclusively because of their
advanced age. In addition, several studies have found that
clinicians will either rule out particular treatments based on
a patient’s age or will give strong recommendations against
particular treatments in patients with colorectal or breast
cancer [25–29].
In a recent survey [30] of physicians who were involved in
TDM with regard to chemotherapy in cancer patients aged
70 years and older, treatment side effects (24.4%), multiple
illnesses (20.5%) and lack of support from family and friends
(10.9%) were reported as challenges. The authors reported
that in addition to the presence of comorbidities, functional
status was among the principal factors physicians consid-
ered when they made such treatment decisions [30].
Older patients are at a higher risk for chemotherapy
toxicities due to physiological changes associated with
aging, potentially causing adverse QOL outcomes [31].
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tancy have been proposed as important considerations in
the TDM of older adults with cancer [32–34]. In fact, older
adults have ranked QOL as a top priority in life [35]. When
asked about the importance between QOL and quantity of
life in relation to their treatment decisions, 97% (N=42) of
older adults (age range 60–85 years, median 71 years) with
acute myeloid leukemia or advanced myelodysplastic syn-
drome shared that QOL, rather than length of life, was an
important factor in their choice of therapy [36].
In summary, there is strong evidence that older patients
with various types of cancer do have personal preferences
and values and contextual factors inﬂuencing their treat-
ment decisions. There is also considerable evidence that
patients want to be informed and consulted with regard to
the impact of treatment on QOL as well as overall survival.
However, no data exist regarding inﬂuential factors that
older adults diagnosed with symptomatic MM consider
during TDM. Moreover, physician factors inﬂuencing treat-
ment decision have not been previously studied in older
adults newly diagnosed with symptomatic MM. It is uncer-
tain how physician factors affect the decision of older adults
with symptomatic myeloma during TDM.
1.2. Purpose
The purpose of this study was to explore patient- and
physician-related factors inﬂuencing treatment decisions
in older adults newly diagnosed with symptomatic MM
(myeloma patients who have end organ damage manifested
as hypercalcemia, renal insufﬁciency, anemia, bony lytic
lesions, neuropathy or neutropenic sepsis). The ﬁrst objec-
tive of the study was to examine the patients’ perspectives
on TDM, including their personal and contextual factors
relevant to TDM. The second objective was to describe
physicians’ perspectives on the TDM in older adults (Z60
years of age) newly diagnosed with symptomatic MM.
2. Methods
2.1. Design
The study employed a descriptive, cross-sectional design
using semi-structured interviews. Since TDM is a complex
health care phenomenon that has not been elaborated in
patients with MM, a qualitative approach was used to
explore the perspectives of patients and physicians during
TDM and to examine the factors inﬂuencing treatment
decisions from both perspectives.
2.2. Sample
The patient sample consisted of older who were newly
diagnosed with symptomatic MM and had been referred to
Seattle Cancer Care Alliance or the Northwestern University
Myeloma Program by hematologists/oncologists in the
greater Seattle or Chicago areas, respectively. To be eligible
for study, patients were (a) older adults (60 years of age and
above); (b) newly diagnosed (6 months from diagnosis) with
symptomatic MM; (c) able to read and write English; (d) ableand willing to give informed consent. The physician sample
consisted of physicians from Seattle Cancer Care Alliance
and University of Washington-afﬁliated clinics and from
Northwestern University Myeloma Program who were
directly providing care to MM patient participants.
2.3. Patient and physician recruitment
Approvals from the University of Washington and North-
western University Human Subjects Divisions to recruit older
adults newly diagnosed with symptomatic MM to participate
in the study were obtained. The researchers made every
attempt to recruit from both university- and community-
based practices to enhance the diversity of study partici-
pants. Eligible participants were recruited by mail using a
recruitment ﬂyer (University of Washington) or a direct
approach (Northwestern University) in the recruitment of
study participants. Physicians from both universities were
recruited via e-mail and by direct approach.
2.4. Procedure
A semi-structured interview was conducted in a designated
research-related conference room at University of Washing-
ton and Northwestern University outpatient cancer clinics.
These rooms were assigned for research use only and met
the standard for patient privacy. Similarly, the physician
interview was conducted in a place where privacy was
secured, such as the physician’s or researcher’s ofﬁce.
Patient participants were asked about the treatment
options discussed by their physicians including risks and
beneﬁts, their preferred role during decision making and
how they make the best treatment decisions for them-
selves. Physician participants were asked to recall their
experiences of how they usually presented treatment
options to patients. They were then asked speciﬁcally about
which factors they consider when making a treatment
decision, their preferences and perceptions of patient
participation during the decision-making process and how
they make the best treatment decision for their patients.
All study interviews were audio-recorded and then tran-
scribed verbatim. Identifying names or proper nouns were not
included in the transcription. All transcripts were checked
against the original audio recording by the researchers.
2.5. Analysis
Directed content analysis procedures [37] were used to
develop major themes from the patient and physician
participant interviews. Initial categories and their deﬁni-
tions were developed based on a literature review of
physician and patient factors inﬂuencing treatment deci-
sions in cancer [38]. Interview text was read line by line by
the lead researcher (JDT) and then imported to NVivo 8
(QSR International, Victoria, Australia), [39] a qualitative
data software analytic program. Initial categories and
deﬁnitions were also imported to NVivo. The minimum unit
of analysis was typically one sentence, but sometimes the
unit was an entire paragraph, depending on whether the
patient shifted the topic in a different direction other than
what was asked in the interview schedule or in follow-up
Table 1 Sociodemographic characteristics of the patient
sample.
Variable N %
Age (mean, 67.45 years)
60–70 14 70
71–82 6 30
Gender
Male 8 40
Female 12 60
Race
Caucasian 18 90
Asian 1 5
American Indian/Native Alaskan Native 1 5
37Patient, physician and contextual factors are inﬂuential in the treatment decision makingprobes. Probes included statements such as, “Tell me more
about the role you have selected,” or “What else are the
inﬂuential factors in your treatment decisions?” If the
interview text matched the deﬁnition of a pre-established
category, that code was assigned to the text. Text that
could not be coded within the initial categories was given a
new category and deﬁnition. Some categories were grouped
together to create major themes. Interview transcripts
were re-coded based on the subsequent identiﬁcation and
deﬁnition of these new themes or other new categories.
Full agreement between researchers A and B in terms of
coding scheme and their deﬁnitions was reached utilizing
the process of consensual validation [40]. Initial and emer-
ging categories were reviewed and discussed among three
members of the research team (researchers A, B and C).
Ongoing in-depth discussions and agreement about the
wording of ﬁnal themes, factors encompassed by major
themes and deﬁnitions were carried out by the researchers
A and B.Work status
Full time 2 10
Working on medical leave 2 10
Not working 2 10
Retired 13 65
Student 1 5
Personal relationship status
Single 2 10
Married or partnered 12 60
Divorced 5 25
Widowed 1 5
Highest level of education
9th–12th grade 5 25
2 years of college 2 10
4 years of college 10 50
Graduate degree 3 15
Annual household income
$18,000 or less 3 15
$18,000 to $35,000 2 10
$35,001 to $55,000 5 25
$55,001 to $85,000 5 25
$85,001 and above 5 253. Results and discussion
3.1. Results
A total of 79 potential participants at Seattle Cancer Care
Alliance and University of Washington-afﬁliated clinics were
sent recruitment letters from October 2009 through July
2010. Of these 79 potential participants, 14 responded to
the mailer (17.7% response rate) and all agreed to partici-
pate in the study. At Northwestern University clinic all six
potential participants who were approached by the
researcher agreed to participate.
A total of 16 physicians were approached from Settle
Cancer Care Alliance, University of Washington-afﬁliated
community clinics and Northwestern University cancer
clinic. Three physicians from Seattle Cancer Care Alliance,
two physicians from University of Washington-afﬁliated
community clinics and ﬁve physicians from Northwestern
University cancer clinic agreed to participate (62.5%
recruitment rate). Informed consent was obtained from all
study participants. Eleven matched patients from Seattle
Cancer Care Alliance physicians, 3 matched patients with
two University of Washington-afﬁliated physicians and
6 matched patients with 5 Northwestern University physi-
cians comprised the total patient and physician study
subjects.
The patient participants sample mean age was 64.7 years
(SD=7.6); mostly Caucasian men and women participated,
with only one Asian and one Native American. The sample of
ten physician participants consisted mainly of women (n=7)
between 30 and 39 years of age (n=8), but with varying
race/ethnicity and title or position in the institution.
Tables 1 and 2 list all demographic information collected
for the patient and physician participants, respectively.
The percent agreement for the coding of patient inter-
view themes and factors were 86.66% and 81.43%, respec-
tively. For physician interview themes and factors, the
percents of agreement were 91.66% and 86.08%, respec-
tively. Given the exploratory nature of this study, the
degree of agreement for coding that was achieved between
researchers A and B was considered acceptable [41]. Ninemajor themes were identiﬁed from the patient interviews
and seven major themes were identiﬁed from the physician
interviews. The major themes with deﬁnitions and frequen-
cies of occurrences for both patient and physician inter-
views are shown in Tables 3 and 4.
Major themes for patient interviews:
Trust in the physician, the health care team and the
institution.
Decisional role preferences vary.
Patients have many sources of information related to MM.
Table 3 Major themes from patient participant inter-
views on TDM.
Themes Deﬁnitions N (%)
Trust in the physician,
healthcare team,
and/or institution
Participants verbally
expressed their trust in
the physician, the
health care team,
and/or the institution
as inﬂuential in
treatment decisions.
This deﬁnition also
includes implicit trust
to the physician by
going along with
physician’s treatment
recommendations or
decisions
20 (100)
Participants have
many sources of
information related
to myeloma
Participants described
the different sources
of myeloma-related
information such the
Internet, physicians,
family and friends who
help do the research
and obtain myeloma-
related materials,
physician visit
companions, books,
pamphlets, nurses,
myeloma patients,
other cancer patients,
and support group such
as the multiple
myeloma ﬁghters and
myeloma or lymphoma
society. This is distinct
from “other’s
opinions” in which the
information or opinion
was identiﬁed as
actually inﬂuencing
the treatment decision
20 (100)
Participants have
various decisional
role preferences
Patients described
their role preferences
or any changes in role
preferences as being
active (patient making
his or own treatment
decision with or
without consideration
of the physician’s
20 (100)
Table 2 Sociodemographic characteristics of the phy-
sician sample.
Variable N %
Age group
30–39 8 80
40–59 2 20
Gender
Male 3 30
Female 7 70
Race
White 5 50
Asian 3 30
African American 2 20
Title or position
Fellow 5 50
Attending physician 3 30
Private practice physician 2 20
Personal relationship status
Single 1 10
Married or partnered 9 90
J.D. Tariman et al.38Patient-speciﬁc and contextual factors inﬂuence treat-
ment decisions (Please see Tables 5 and 6 for exemplars,
respectively).
Negative perceptions of the TDM process.
Treatment decisions are driven by the beneﬁts of being
cancer-free, the desire to be in remission, and the desire to
live a longer life.
State of shock at the time of diagnosis.
Hope for advances in science.
Major themes for physician interviews:
Physicians consider QOL or OS alone or simultaneously
considers treatment effectiveness, QOL, and OS.
Physician-speciﬁc factors inﬂuenced decision making
(Please refer to Table 7 for exemplars).
Strong considerations of eligibility for Autologous HSCT.
Limited time is a major barrier to effective TDM.
Physicians use various ways of assessing patient decisional
role preferences.
The patient ultimately makes the ﬁnal treatment
decision.
When needed, physicians attempt to persuade patients to
take their recommended treatment option.opinion), shared
(patient and physician
share responsibilities
in making the
treatment decision),
or passive (patient
delegating the
treatment decision to
the physician) or4. Discussion
The ﬁndings from this study document many themes and
factors considered by physicians and patients with sympto-
matic MM during TDM. There are some similarities between
the physician and patient results regarding inﬂuential
factors for treatment selection such as QOL, convenience,
Table 3 (continued )
Themes Deﬁnitions N (%)
changes in their role
preferences outside of
the context of being in
a state of shock
Patient-speciﬁc
factors inﬂuence
treatment decisions
Patient-speciﬁc factors
refer to patient’s
actual experience with
myeloma-related
therapy, age, beliefs
and values, faith in a
higher power, opinions
of family, opinions of
others, past health-
related experience not
related to myeloma,
and self description of
“What I’m like”
inﬂuencing treatment
decisions. This theme
will be coded along
with the patient-
speciﬁc factor
19 (95)
Negative perceptions
of treatment
decision making
Patients described
negative perceptions
of treatment decision-
making such as lack of
discussion of
treatment options,
long periods of waiting
during the encounter,
inability to reach a
health care team
member, and wanting
to have more
information related to
disease, prognosis,
treatment, and side
effects or having
questions left
unanswered, not
achieving the desired
level of participation
17 (85)
Treatment decisions
are driven by the
beneﬁts of being
cancer-free, the
desire to be in
remission, and the
desire to live a
longer life
Patients described the
beneﬁts of their
therapy such as being
cancer-free, killing the
cancer cells (patients
also describe their
myeloma marker at
0 level), being in
remission, and living a
long life
15 (75)
Contextual factors
inﬂuence
treatment decisions
Patients’ contextual
factors refer to issues
of health insurance,
ﬁnancial status,
availability of free
medication regardless
14 (70)
Table 3 (continued )
Themes Deﬁnitions N (%)
of insurance,
geographical barriers,
treatment costs, social
support, housing/
lodging, retirement
planning, recent
signiﬁcant events in
the family, and
transportation/
convenience of oral
therapy at home
inﬂuencing treatment
decisions. This theme
will be coded along
with the speciﬁc
contextual factor
Some participants
were in a state of
shock at the time of
diagnosis
Participants described
being in a state of
shock, feeling very
overwhelmed and not
at the right frame of
mind, unable to
process what was
heard from the
physicians during the
visit, feeling pretty
much out of it or kind
of in a fog, and feeling
paralyzed from
participating in
treatment decision
making
6 (30)
Advances in science
provide hope for
future treatment
options
Participants described
advances in science
provide hope for
future treatment
options but not
inﬂuencing their
current treatment
decision
4 (20)
39Patient, physician and contextual factors are inﬂuential in the treatment decision makinginsurance, cost, family opinion, age, patient’s medical and
clinical factors and social support considerations. These
multidimensional factors are simultaneously weighted by
patients and physicians to make the “best decision” in the
setting of clinical uncertainty. Berry and colleagues [42]
have previously reported similar personal factors that were
inﬂuential in the treatment choices of men diagnosed with
localized prostate cancer, including: age, cancer in the
family, family responsibilities and desire for longevity, as
well as physician factors that included consideration of the
patient’s comorbidity and pathology.
Maintaining QOL during therapy was very important, not
only from the patient’s perspective but also from the
physician’s point of view. Among the contextual factors
Table 4 Major themes from physician participant inter-
views on TDM.
Themes Deﬁnitions N (%)
Physicians consider
QOL or survival
alone or
simultaneously
consider QOL,
treatment
effectiveness, and
survival
Some physicians
describe QOL or
survival consideration
and some physicians
simultaneously
consider multiple
factors including
efﬁcacy, QOL, and
survival in their
treatment decisions.
This theme is also
coded when the
physician mentions
morbidity, mortality,
and life expectancy
considerations when
making treatment
decisions
10 (100)
Physician-speciﬁc
factors inﬂuence
treatment decisions
These are aspects of
the physician’s life
that inﬂuence
treatment decisions.
These factors include
patient’s context,
patient’s family
opinion, patient’s co-
morbidities, functional
status, and supportive
care requirement,
patient’s treatment
preference, patient’s
age, patient’s medical
and clinical factors,
physician’s beliefs and
values, and physician’s
expertise and type of
practice. This theme is
coded in conjunction
with the speciﬁc
physician factors
10 (100)
Eligibility for
autologous HSCT is
an important
treatment
consideration
Physicians evaluate
their patients’ overall
medical condition for
eligibility for
autologous stem cell
transplantation
9 (90)
Physicians use various
ways of assessing
patient decisional
role preferences
Physicians share that
they have no
systematic tool to
assess preference;
sometimes they ask or
sometimes they
indicate they just have
a feeling for the
patient’s role
preference. This
theme does not
9 (90)
Table 4 (continued )
Themes Deﬁnitions N (%)
include the physician’s
own description of the
decisional role of
patients
Barriers to effective
decision making
Physicians describe
limited time and lack
of long term outcome
data as barriers to
effective decision
making; physicians
share that there is a
need to spend more
time talking with
patient
7 (70)
The patient
ultimately makes
the treatment
decision
Physicians describe
providing different
treatment options to
patients, explaining
risk and beneﬁts, and
speciﬁcally state that
patient ultimately
makes the ﬁnal
decision. This does not
include physician’s
belief on patient
participation or non-
participation with
decision making
5 (50)
When needed,
physicians attempt
to persuade
patients to take the
physician’s
recommended
treatment option
Physicians describe
presenting strong
treatment
recommendations to
patients when patients
make illogical
decisions
2 (20)
Abbreviations: QOL=quality of life; TDM=treatment decision
making; HSCT=hematopoietic stem cell transplantation.
J.D. Tariman et al.40described by patient participants, the convenience of oral
chemotherapy has been described as inﬂuential in the
treatment decisions. Since a pill can be conveniently taken
at home, a decision for oral chemotherapy translates to
fewer visits to the clinic, ultimately impacting patient’s
QOL. This option is very attractive to older adults above the
age of 70 years, because it offered them more indepen-
dence and required less family burden to complete the
therapy since they don’t need to ask family members to
drive them to the clinic.
QOL and independence are values that are consistently
ranked by older adults as their top priorities in life [35,36].
Husain et al. [43] have also reported QOL and independence
as inﬂuential factors in the treatment choices by older
women (470 years of age) with breast cancer. For physician
participants in this study, oral chemotherapy is appealing as
long as the patients can adhere to the prescribed therapy
and treatment efﬁcacy is not compromised. Kreling et al.
Table 5 Patient-speciﬁc factors that inﬂuenced treatment decisions.
Factors Deﬁnitions Exemplar quote N (%)
Actual
experience
with
therapy
Participant’s actual experience with therapy speciﬁc for
their myeloma such as reaction, side effects, response or
non-response to therapy inﬂuence subsequent decisions.
This deﬁnition does not include experiences with
therapies not related to myeloma (included in the
deﬁnition of past health-related experiences)
“I had unfavorable reactions to the
medication I was taking. I started
developing neuropathy in my hands and
feet. My doctor consulted a myeloma
specialist and my treatment was changed”
16 (80)
Beliefs and
values
Participants’ personal belief about the necessity of
completing a therapy or belief in the outcomes of a
speciﬁc therapy and the participants’ valuation of: QOL,
independence, and not being a burden to family as
inﬂuences on their treatment decisions. Beliefs and
values are different from the perceived beneﬁts of
treatment
“I just think this cancer is very tricky and
that we have to out-trick it. So I think
novel treatments are where I see the
greatest potential of a longer life for
people like me. That’s why I chose the
clinical trial involving novel agents”
16 (80)
Opinions of
family
Participants’ solicitation and consideration of the
opinions of family inﬂuenced treatment decisions; a
speciﬁc link between family opinions and treatment
choice was identiﬁed
“My children very much wanted me to ﬁght
this to the bitter end and regain my life
back, because I think it was very hard for
them to see me in an invalid kind of stage
where they had to care for me at the
beginning, and I’m always the one caring
for them”
9 (45)
Age Participants who described themselves as being at a
particular age category and feeling healthy or being in a
particular age, regardless of health status, had
inﬂuenced their treatment decision
“Well, the option that was not seriously
considered was stem cell transplantation;
because of my age [80 years] that was
ruled out”
9 (45)
Opinions of
others
Participant’s solicitation and consideration of the
opinions of non-family members inﬂuenced treatment
decision; a speciﬁc link between opinions of others and
treatment choice was identiﬁed
“The thing that did inﬂuence me a lot was I
talked to a gentleman during chemo that
had gone through the stem cell and he was
telling me how he had eight absolutely
wonderful years where he traveled and he
was free of cancer and he got his life back”
8 (40)
Past health-
related
experience
Participant’s own past health-related (e.g., overall good
health, past illness experience) and therapy-related
experiences (not relating to myeloma) inﬂuenced
participants’ treatment choice
“I had 21 operations in my life. I’ve come
through all that. This is just another step in
my life and I’ll come out the other end
smiling. So that is why I decided to take the
decision of having an auto stem cell
transplant”
6 (30)
“What I'm
like”
Participants who identiﬁed what they were like as a
person – their job, their personality – inﬂuenced
treatment decisions
“I didn’t see any reason to question there
was an alternative to this cutting edge
treatment [auto stem cell transplant]. It
seemed to me I’m a cutting edge guy so it
appealed to me.”
5 (25)
Faith in a
higher
power
Participants described praying to a higher power and
faith in a higher power as an inﬂuence in their treatment
decision
“I prayed to God to give me the best
treatment and the best doctor”
5 (25)
41Patient, physician and contextual factors are inﬂuential in the treatment decision making[52] have reported some similarities in what they called
patient’s contextual factors inﬂuencing treatment decision
in older women (Z65 years of age) with breast cancer,
including the patient’s age, functional status, comorbidities
and perceptions of the beneﬁts and side effects of
chemotherapy.
The patient participants were making treatment choices
based on contexts in their lives. For example, the avail-
ability of support from family and friends inﬂuenced the
patients’ choice of HDT because it requires a signiﬁcant
time commitment and caregiver support during the acutephase of therapy (typically days 1–30 post-transplant). From
the physician’s perspective, the participants were cognizant
of patient preferences and contextual factors and offered
treatment recommendations with strong consideration of
the patient’s personal factors and social contexts. The
physician participants talked about the importance of
assessing a patient’s ﬁnancial, logistical and social support
status and how these factors inﬂuenced their treatment
recommendations to their patients. One study [45] has
reported family burden, cost and travel requirements as
important factors inﬂuencing the physician’s decision to use
Table 6 Contextual factors that inﬂuence treatment decisions.
Factor Deﬁnition Exemplar quote N (%)
Social support Availability of family and/or friends to provide
caregiver support during therapy – including
attendance at the physician or clinic visits or
availability of family members to take some household
responsibilities, being single, family, and caregiver
burden – inﬂuenced treatment decision
“My wife is an absolute jewel. She insists
on taking care of my every need and she
invents some needs I probably don’t think
about. My concern is if she will wear
down. She’s 83 and she has a lot of energy
and she’s a wonderful caregiver, but
I worry that I may wear her down”
9 (45)
Insurance The type of insurance coverage for a particular therapy
inﬂuenced participants’ treatment choice
“We were glad that we have very good
insurance coverage. For two transplants,
I was adamant that any procedure I do, it
has to be certiﬁed and pre-approved [by
the insurance company]”
5 (25)
Transportation
issues/
convenience of
pills
Travel issues from home to clinic to home – such as
availability of a driver or the ability of the participant
to drive a car, or the convenience of taking oral
chemotherapy at home – inﬂuenced treatment
decisions
“Basically my doctor offered either the IV
or the Revlimid by pill. I felt that well,
I guess the pill was more appropriate for
quality of life from my standpoint. It’s
easier to do, it gives me more ﬂexibility,
and I don’t have to keep going in to the
clinic every day”
5 (25)
Geographic
barrier
Participants described the actual distance and amount
of time to travel to get the therapy inﬂuenced
treatment decision and the need for housing or lodging
during therapy due to distance of medical institution
for the participant’s residence
“I considered Mayo. I have a relationship
with them from many years ago, but
I wanted to be in town [Chicago]. I’m
impressed with the team in Northwestern
facility and it also has the advantages of it
being near my three daughters and my
wife so that I didn’t see any reason to go
anywhere else”
5 (25)
Finances The participant verbally expressed that the amount of
money the participant has to pay out of his own pocket
to get the therapy and costs of retirement inﬂuenced
treatment decision. This factor includes participants
getting free medication instead of paying several
thousands of dollars for their chemotherapy
“I’m running on empty [ﬁnances] now. So I
do take that into account”
5 (25)
J.D. Tariman et al.42adjuvant chemotherapy among older adults (Z65 years of
age) diagnosed with stage III colon cancer, but these
contextual factors were not ranked as important as
patients’ comorbidities and medical evidence for treat-
ment. There are some similarities in the patient-speciﬁc
factors (i.e., age, past health-related experience, insur-
ance, social support, family burden, geographic barrier)
inﬂuencing treatment decisions when compared to patient-
speciﬁc factors of other older patients diagnosed with
cancer. However, some personal and social contexts (i.e.,
actual experience, some aspects of personal beliefs and
values, opinion of others, signiﬁcant events in the family,
convenience of oral pills and faith in high power) varies
from the personal and social contexts in patients with
breast, prostate, colorectal and ovarian cancer.
At a certain point, age becomes inﬂuential in the treat-
ment choice; in general, physician participants consider 70 as
the cut-off age for HDT. In this study, patient participants also
consider their own particular age as inﬂuential in their
treatment choice. For example, patient participants who
were under 65 years (n=14) considered themselves as strongcandidates for HDT, while those who were 70 years and above
(n=6) did not consider HDT. The older patient’s preference
for HDT or non-intensive therapy could have been inﬂuenced
by their physician’s recommendation, as this study has
documented. Kutner et al. [45] have reported similar
patient-reported considerations of the physician’s decisional
factors. Notwithstanding this, some physician participants in
this study would still consider HDT for patients above the age
of 70, provided that the patient has good performance status
and no comorbidities. Physician participants strongly consid-
ered treatment effectiveness and OS, albeit while keeping an
eye on the patient’s QOL. The patient’s age has been
reported as inﬂuential by both patient and physician as a
factor in their treatment decisions in patients with breast and
prostate cancers [42,45].
It was not surprising that both the patient (r65 years of
age) and physician participants were considering HDT. HDT
using high-dose intravenous melphalan followed by auto-
logous HSCT is considered an important treatment option
for MM patients under the age of 65 [46–48]. More studies
are needed to develop innovative methods to help both
Table 7 Physician-speciﬁc factors inﬂuencing treatment secisions.
Factors Deﬁnitions Exemplar quotes N (%)
Patient’s co-morbidities,
functional status, and
supportive care
requirements
Physicians describe presence of
comorbidities, poor or good functional
status, and supportive care issues
inﬂuencing choice of chemotherapy
approach
“Other medical conditions, performance
status, if they’ve had complications with
the chemo before. Primarily comorbid
conditions and their performance status
would make me choose a less intensive
approach”
10 (100)
Physician’s beliefs and
values
Physician’s personal beliefs on patient–
physician relationship dynamics; beliefs
that the patient doesn’t have much
knowledge, need for oversimpliﬁcation,
need for slowly introducing myeloma
concepts, and patient asking the physician
to talk about what treatment physicians
would choose if it were them; beliefs that
patients should or should not participate in
decision making; belief that myeloma
decisions are becoming more technically
difﬁcult to understand for the patient
inﬂuence treatment decisions
“I think that would still involve me being
very active – because I believe in
transplantation I think that I would be – try
to be very convincing to – that would be
wise. Because that’s the approach I believe
in”
10 (100)
Patient’s Context Physicians consider the patients’
contextual factors such as health
insurance, ﬁnancial status, availability of
free medication regardless of insurance,
geographical barriers, treatment costs,
social support, housing/lodging issue,
transportation/convenience of oral
therapy at home, and treatment
compliance issues as inﬂuential factors in
treatment
“The patient’s overall situation could alter
my decision; their ability to come to the
doctor, their ability to follow-up, could
decide whether I would pick a non-
transplant or transplant approach”
9 (90)
Patient’s medical and
clinical factors
Physicians consider patient-speciﬁc
medical and clinical factors such as type of
myeloma, high-risk disease features by
cytogenetics, ﬂuorescent in situ
hybridization (FISH) test, or genomics,
positive response or resistance to therapy,
patient’s actual experience with therapy,
and any end-organ damage as inﬂuential
factors in treatment selection
“The prognostic indicators of the
cytogenetics of the bone marrow will also
lead a little bit your decision making, and
the treatment of multiple myeloma in the
sense that if you have deletion 17, we
know that myeloma won’t be responsive to
thalidomide or lenalidomide or the
“-imides” in general. Therefore, you would
start an induction treatment with
bortezomib typically”
7 (70)
Physician’s expertise and
type of practice
The physician’s expertise in stem cell
transplantation and practice type
(transplant center) inﬂuence treatment
choice
“I think to some degree it’s our own bias
because we are a transplant center and I
and most of my colleagues continue to
believe that for the appropriate age and
health condition, transplant is of value.
And so I deﬁnitely approach a new patient
with the idea of determining if they’re a
suitable patient for transplant”
6 (60)
Patient’s Age Consideration of patient’s age (at 70 or
older) regardless of other factors,
inﬂuenced choice of a non-transplant
option or very young myeloma patients
aged 40–50 years old tending to have very
aggressive treatment such as high dose
chemotherapy. Age-related issues in the
context of stem cell transplant discussion
was coded under eligibility for HSCT
“I choose certain drugs for patients who
are age 70 and over; certainly over this age
we would consider non-transplant drugs”
6 (60)
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Table 7 (continued )
Factors Deﬁnitions Exemplar quotes N (%)
Patient’s treatment
preference
Patient’s expressed preference for a
speciﬁc therapy inﬂuenced treatment
choice
“If they[patients] say they just want pills
and they understand all of the upsides and
downsides, then sure”
5 (50)
Family opinion Family member’s opinion being weighed in
by physicians as an inﬂuence in their
treatment choice, but does not include
physician’s mention of the presence of a
family member during patient–physician
encounters
“The older the patient the more likely you
are to have other family members
involved. More than just the spouse. It
might be the daughter, or the kids
involved. It is important to get to the point
where everyone is comfortable and
understands what, and is in agreement
with the goals of treatment”
3 (30)
Clinical trials as an option Offering a clinical trial as a treatment
option regardless of availability of free
medication inﬂuenced treatment decisions
“For the patients over age 70 or certainly
over age 75, we’d either be considering our
clinical trial, which is lenalidomide/
dexamethasone until progression, lenalido-
mide/dexamethasone for 18 months, or
alkeran/predni-sone/thalidomide”
2(20)
J.D. Tariman et al.44patients and physicians reach a consensus on which treat-
ment approach (i.e., HDT versus non-intensive) is best to
take in a given context. Furthermore, more studies are
needed to help physicians develop clinical decision path-
ways or treatment decision algorithms with regard to
screening patients for eligibility for HDT followed by APBSC
in order to have some general guidelines for non-myeloma
specialists.
There was evidence of discordance between the physi-
cian and patient’s perspectives with regard to who the
decision maker actually should have been. The majority of
the patient participants perceived that the physicians made
the decision for them. This belief ran somewhat contrary to
many physicians’ statements that it was ultimately the
patients who made the treatment decision. This is an
interesting ﬁnding, and one that requires further investiga-
tion. In patients who were in shock at the time of diagnosis,
it is conceivable that the physicians presented several
options to patients, who were unable to recall the options
that were offered due to difﬁculty processing all informa-
tion. It is also possible that when physicians made a strong
recommendation for a particular option, the patients may
have perceived that they didn’t have enough knowledge
about the different options and therefore they would leave
the decision to their physician, who ultimately made the
decision for them. In other qualitative studies in men
diagnosed with prostate cancer [49] and women with
ovarian cancer, [44] the treatment decision also seemed
to be driven mostly by the physicians, with some patients
perceiving themselves as passive recipients of care. Future
research should seek to uncover whether physicians can
present treatment options with more equipoise and whether
patients who desire a more shared or active decisional role
can be given the opportunity by their physicians to partici-
pate more fully in the actual decision making.
Limited time has been reported as one of the barriers to
effective treatment decision-making [50]. The study ﬁnd-
ings described above have conﬁrmed that this negativeaspect of TDM was pervasive. Both patient and physician
participants acknowledged that the time allotted for TDM
discussion was limited and not sufﬁcient to fostering the
kind of discussion of options needed to reach a tailored or
“best” treatment decision. The onus is with the physician to
provide patients ample time to process the treatment
options that they are offering to their patients. Poor quality
patient–physician communication has been identiﬁed as one
of the challenges in TDM [51] and is also an area that
requires further investigation. Studies that can guide
administrative policies on adequate time allocation in terms
of treatment decision encounters would be very beneﬁcial
not only for the patients but also for the physicians.
Past health experiences and actual experience with MM
therapy have been found to be inﬂuential in the treatment
considerations by older MM patients in this study. These
ﬁndings have been previously reported in studies conducted
in older women (Z70 years of age) with breast cancer. For
example, Husain et al. [43] reported that two women in
their study strongly preferred a speciﬁc treatment based on
their previous health care experience. The researchers
found that these women did not consider the treatment
information provided by their clinicians; instead they simply
requested a speciﬁc treatment based on their personal
experience with breast cancer therapy. Kreling et al. [52]
have found that women who underwent chemotherapy
experienced side effects that were more uncomfortable
than what they have expected with one subject who
eventually requested a change on her chemotherapy regi-
men due to the devastating effect of alopecia on her mental
health.
In this study, family opinions and opinions of others
including a second physician opinion have been considered
by older MM patients as having an inﬂuence in their
treatment decisions. Other TDM studies in patients with
prostate, [13] ovarian, [44] breast, [43,52] and colorectal
cancer [45] have also found these factors as having an
inﬂuence on treatment decisions.
45Patient, physician and contextual factors are inﬂuential in the treatment decision makingThe issue of therapy cost and its eventual impact on
personal ﬁnances has been described previously as inﬂuen-
tial factors in TDM [45,53]. In this study, some patient
participants related how they made sure that their insur-
ance covers the treatment that they were going to have so
as to avoid any negative impact on their personal ﬁnances.
Some of them take into account the actual co-pays and out-
of-pocket cost when they made their treatment decisions.
The physician’s expertise and practice type have been
previously reported as having an inﬂuence in treatment
selection. For example, one study [54] found that Hodgkin
disease experts are more likely to individualize patient’s
therapy than non-Hodgkin expert physicians and academic
physicians are more likely to choose combined modality
therapy (CMT) over radiation therapy or chemotherapy
alone. Similarly, in patients with localized prostate cancers
(LPC), a survey showed that urologists tend to favor surgery
while radiation oncologists tend to favor radiation therapy
over surgery [55]. In an international survey, gastroenterol-
ogists tend to favor surgery for the management of gastric
lymphoma, while hematologists and oncologists are more
inclined to favor conservative therapy [56]. In this study,
the majority of physician participants (N=8) work in a MM
practice with a strong HSCT program. This would have a
clear inﬂuence in TDM as far as screening patients for
autologous HSCT eligibility. This study showed that 9 out
10 physician participants screened their patients for auto-
logous HSCT eligibility. There was only one physician parti-
cipant who did not mention screening for autologous HSCT.
5. Limitations
This study was limited by the exploratory nature of the
design, limiting generalizability beyond the setting of a
comprehensive cancer center. Also, the sample was not
diverse with respect to race and ethnicity; African Amer-
icans and Hispanic patients with myeloma were not repre-
sented in this study. Moreover, the participants in the study
were mostly with high level of education, achieving at least
2 year college level education. Lastly, since this is a cross-
sectional study, the ﬁndings may not be applicable to
symptomatic myeloma patients who are beyond 6 months
of diagnosis. Further study using a longitudinal approach is
needed to better describe the changes in study participants’
inﬂuential factors during TDM over time, especially in older
adults diagnosed with cancer.
6. Conclusion
Older MM patients (Z60 years of age) with symptomatic MM
consider personal, social and contextual factors during TDM.
These factors include actual experience with MM therapy,
physician’s opinion, personal beliefs and values, family
opinion, family burden, social support, insurance and con-
venience of therapy as inﬂuential factors in their treatment
decisions while physicians treating older patients with
symptomatic MM consider the patient’s comorbidities, per-
formance status, supportive care requirements, their own
personal beliefs and values, patient’s medical and clinical
factors, patient’s context, family opinion and patient’s
treatment preference as having an inﬂuence on theirtreatment decisions. Though there are similarities in both
patient- and physician-speciﬁc inﬂuential factors, some
differences exist and must be seriously considered in actual
TDM to improve decisional satisfaction. Therefore, it is
critical that patients are given the opportunity to choose
the best possible treatment for their MM within the limits of
the patient’s personal, social and medical contexts. In the
future, it would be easier to guide MM patients with
symptomatic disease make treatment decisions using prob-
abilistic model if RCTs clearly show which therapy provides
better QOL and OS outcomes for the patients.
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